An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA® Analysis of patient mobility indicated patients treated with ZILRETTA walked more steps per day in concert with pain reduction Survey of 1,000 patients with
BURLINGTON, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020 . Flexion’s management will host a conference call at
New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of
BURLINGTON, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19 th Annual Needham Virtual Healthcare Conference. The
BURLINGTON, Mass. , April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to seven new employees consisting of 9,265 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date
Company signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of ZILRETTA® in Greater China License agreement provides Flexion with $10 million upfront payment, up to
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $73.0 million for full-year 2019, representing more than 220% growth over 2018 Analysis of Phase 3b trial investigating ZILRETTA in patients with knee OA and synovitis indicates treatment
BURLINGTON, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins Flexion with more than 25 years of commercial experience within the life science industry.
BURLINGTON, Mass. , March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8,500 stock options and 1,500 restricted stock units. The Compensation Committee of the Board of Directors
BURLINGTON, Mass. , March 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020 .
